

## Special Issue

# Immune-Mediated Skin Diseases: From Pathophysiology to Novel Therapeutic Approaches

### Message from the Guest Editors

Growing interest in the pathogenesis of immune-mediated skin diseases (skin IMIDs) has led to the identification of several inflammatory pathways that are crucial for their development and maintenance.

Dermatologists can be considered sentinel clinicians in the development of systemic involvement related to skin IMIDs, they can play a significant role in modifying the natural history of skin IMIDs through early recognition and therapeutic interventions.

In recent years, research has led to highly effective new treatment options, and others are expected in the near future. However, the following questions remain: What are the main pathological drivers of skin IMIDs? What is the role of the skin microenvironment? What are the mechanisms underlying systemic involvement in skin IMIDs? Are there predictive biomarkers for systemic targeted treatments? Can an early therapeutic intervention really change the natural history of skin IMIDs and their systemic repercussions?

This Special Issue intends to provide plausible answers to these and other questions by presenting the latest research on skin IMIDs, as well as highlighting research gaps that should be addressed in future studies.

### Guest Editors

Dr. Anna Campanati

Dr. Emanuela Martina

Prof. Dr. Annamaria Offidani

### Deadline for manuscript submissions

closed (31 December 2021)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/76526](https://mdpi.com/si/76526)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).